Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release third quarter 2020 financial results after market close on Monday, November 9, 2020. Following the release, the Company will host a live confer

Click to view original post